Sensirion's rating has been upgraded by UBS from "sell" to "buy," with the price target raised from CHF 68 to CHF 84.
The analyst believes that positive indicators suggest the end of the destocking phase and expects the high-margin medical technology division to resume growth by 2025.
The industrial division has already shown improvements, benefiting from increased demand for air purifiers in the first half of 2024.
As a result of this upgrade, Sensirion's share price has significantly increased, reflecting investor confidence in the company's future performance.